BioNTech (Mfg Services) vs Merck KGaA / MilliporeSigma (CDMO): CDMO Comparison

Side-by-side comparison of BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Mainz, DE · Marburg, DE
Signal Score
85/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
8
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
24
Capacity
Modalities
mRNA
Darmstadt, DE · St. Louis, MO
Signal Score
82/100
Quality (FDA + GMP)
99/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
2
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
22
Capacity
Modalities
mRNA, Biologics, Cell Therapy

Key differences

  • Merck KGaA / MilliporeSigma (CDMO) has FDA inspections on record (2); BioNTech (Mfg Services) does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • BioNTech (Mfg Services) has materially broader EMA GMP coverage (8 active certificates vs 2) — stronger EU footprint.

On a 13-modality CDMO landscape, both BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) qualify as mRNA/LNP manufacturers; BioNTech (Mfg Services) carries the higher composite Signal Score for mRNA/LNP programs in this comparison.

What to evaluate for mRNA/LNP programs

Both BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

See all mRNA/LNP CDMOs ranked by Signal Score →

Frequently asked: BioNTech (Mfg Services) vs Merck KGaA / MilliporeSigma (CDMO)

Which has the stronger FDA inspection record, BioNTech (Mfg Services) or Merck KGaA / MilliporeSigma (CDMO)?

Both BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioNTech (Mfg Services) has 0 FDA inspections on record; Merck KGaA / MilliporeSigma (CDMO) has 2.

How do BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) compare on European GMP coverage?

BioNTech (Mfg Services) holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — BioNTech (Mfg Services) or Merck KGaA / MilliporeSigma (CDMO)?

BioNTech (Mfg Services) is matched to 24 ClinicalTrials.gov records as a manufacturing partner; Merck KGaA / MilliporeSigma (CDMO) is matched to 22. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for mRNA/LNP manufacturing — BioNTech (Mfg Services) or Merck KGaA / MilliporeSigma (CDMO)?

Both BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

BioNTech (Mfg Services) carries a Signal Score of 85/100 and Merck KGaA / MilliporeSigma (CDMO) carries 82/100 — essentially tied for BioNTech (Mfg Services). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating BioNTech (Mfg Services) and Merck KGaA / MilliporeSigma (CDMO) for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.